25K Stock Overview
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Karyopharm Therapeutics Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.36 |
52 Week High | US$4.16 |
52 Week Low | US$0.60 |
Beta | 0.0025 |
1 Month Change | 14.38% |
3 Month Change | 66.30% |
1 Year Change | -59.92% |
3 Year Change | -85.01% |
5 Year Change | -72.85% |
Change since IPO | -95.55% |
Recent News & Updates
Recent updates
Shareholder Returns
25K | DE Biotechs | DE Market | |
---|---|---|---|
7D | 11.2% | 1.2% | 2.5% |
1Y | -59.9% | 34.7% | 7.0% |
Return vs Industry: 25K underperformed the German Biotechs industry which returned 34.7% over the past year.
Return vs Market: 25K underperformed the German Market which returned 7% over the past year.
Price Volatility
25K volatility | |
---|---|
25K Average Weekly Movement | 21.4% |
Biotechs Industry Average Movement | 5.7% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 25K's share price has been volatile over the past 3 months.
Volatility Over Time: 25K's weekly volatility has increased from 15% to 21% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 325 | Richard Paulson | https://www.karyopharm.com |
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Karyopharm Therapeutics Inc. Fundamentals Summary
25K fundamental statistics | |
---|---|
Market cap | €157.87m |
Earnings (TTM) | -€132.65m |
Revenue (TTM) | €135.37m |
1.2x
P/S Ratio-1.2x
P/E RatioIs 25K overvalued?
See Fair Value and valuation analysisEarnings & Revenue
25K income statement (TTM) | |
---|---|
Revenue | US$146.03m |
Cost of Revenue | US$4.94m |
Gross Profit | US$141.09m |
Other Expenses | US$284.19m |
Earnings | -US$143.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.24 |
Gross Margin | 96.62% |
Net Profit Margin | -97.99% |
Debt/Equity Ratio | -222.7% |
How did 25K perform over the long term?
See historical performance and comparison